^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    agerafenib (RXDX-105)

    i
    Other names: RXDX-105, CEP-32496, AC013773, RXDX 105, RXDX105, CEP32496, CEP 32496, AC 013773
    Company:
    Daiichi Sankyo, Roche
    Drug class:
    BRAF inhibitor, RET inhibitor, CS-1 inhibitor
    Related drugs:
    Apply
    Continued Access to RXDX-105 (NCT03784378)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Completed
    Last update posted :
    10/05/2020
    Initiation :
    12/14/2018
    Primary completion :
    09/30/2020
    Completion :
    09/30/2020
    BRAF
    |
    agerafenib (RXDX-105)
    Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors (NCT01877811)
    Phase 1
    Hoffmann-La Roche
    Completed
    Last update posted :
    04/25/2019
    Initiation :
    06/01/2013
    Primary completion :
    12/01/2018
    Completion :
    02/01/2019
    BRAF
    |
    BRAF V600E • BRAF V600
    |
    agerafenib (RXDX-105)